Table 1.
Patient, tumor, and treatment characteristics (n = 23).
| Age (years), Median (range) | 76 (57–84 years) |
|---|---|
| Gleason-score | |
| 6 | 1 (4.4%) |
| 7a | 11 (47.8%) |
| 7b | 11 (47.8%) |
| Tumor stage | |
| cT1c | 2 (8.7%) |
| cT2a | 12 (52.2%) |
| cT2b | 6 (26.1%) |
| cT2c | 3 (13.0%) |
| Risk stratification according to NCCN | |
| Favorable intermediate risk | 7 (30.4%) |
| Unfavorable intermediate risk | 16 (69.6%) |
| Staging imaging modalities | |
| MRI | 23 (100.0%) |
| WBBS | 8 (34.8%) |
| CT | 4 (17.4%) |
| PSMA PET-CT | 1 (4.4%) |
| PSA value prior to RT (ng/mL) | |
| <10 ng/mL | 19 (82.6%) |
| ≥10 ng/mL | 4 (17.4%) |
| Additional ADT | 7 (30.4%) |
n—number of patients, NCCN—National Comprehensive Cancer Network, MRI—magnetic resonance imaging, WBBS—whole body bone scintigraphy, CT—computed tomography, PSMA PET-CT—prostate-specific membrane antigen–positron emission tomography–CT, PSA—prostate-specific antigen, RT—radiotherapy, ADT—androgen deprivation therapy.